

# Jerome Galon

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2219760/jerome-galon-publications-by-year.pdf>

**Version:** 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

200  
papers

36,198  
citations

76  
h-index

190  
g-index

231  
ext. papers

45,193  
ext. citations

10.3  
avg, IF

7.45  
L-index

#	Paper	IF	Citations
200	Immune sunrise: from the immunome to the cancer immune landscape.. <i>Oncolmunology</i> , <b>2022</b> , 11, 2019896	7.2	1
199	The "Immunoscore" in rectal cancer: could we search quality beyond quantity of life?. <i>Oncotarget</i> , <b>2022</b> , 13, 18-31	3.3	0
198	Tissue-resident FOLR2 macrophages associate with CD8 T cell infiltration in human breast cancer.. <i>Cell</i> , <b>2022</b> ,	56.2	4
197	Tumor-Infiltrating Lymphocytes (TILs) in Early Breast Cancer Patients: High CD3+, CD8+, and Immunoscore Are Associated with a Pathological Complete Response. <i>Cancers</i> , <b>2022</b> , 14, 2525	6.6	0
196	Therapeutic Implications of the Immunoscore in Patients with Colorectal Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6	5
195	Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy). <i>Journal of Translational Medicine</i> , <b>2021</b> , 19, 238	8.5	1
194	Prognostic assessment of resected colorectal liver metastases integrating pathological features, RAS mutation and Immunoscore. <i>Journal of Pathology: Clinical Research</i> , <b>2021</b> , 7, 27-41	5.3	9
193	Evasion before invasion: Pre-cancer immunosurveillance. <i>Oncolmunology</i> , <b>2021</b> , 10, 1912250	7.2	1
192	Tumor spread or siege immunity: dissemination to distant metastasis or not. <i>Oncolmunology</i> , <b>2021</b> , 10, 1919377	7.2	0
191	Expand to shield: IL-15 and lymphocytic proliferation. <i>Oncolmunology</i> , <b>2021</b> , 10, 1886726	7.2	1
190	Precision immunity: Immunoscore and neoadjuvant treatment in bladder cancer. <i>Oncolmunology</i> , <b>2021</b> , 10, 1888488	7.2	3
189	Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 2755-2763	12.9	5
188	Germline genetic contribution to the immune landscape of cancer. <i>Immunity</i> , <b>2021</b> , 54, 367-386.e8	32.3	27
187	Compromised nuclear envelope integrity drives TREX1-dependent DNA damage and tumor cell invasion. <i>Cell</i> , <b>2021</b> , 184, 5230-5246.e22	56.2	16
186	The Immunoscore in Localized Urothelial Carcinoma Treated with Neoadjuvant Chemotherapy: Clinical Significance for Pathologic Responses and Overall Survival. <i>Cancers</i> , <b>2021</b> , 13,	6.6	6
185	Gutting it Out: Developing Effective Immunotherapies for Patients With Colorectal Cancer. <i>Journal of Immunotherapy</i> , <b>2021</b> , 44, 49-62	5	1
184	License to kill: microsatellite instability and immune contexture. <i>Oncolmunology</i> , <b>2021</b> , 10, 1905935	7.2	2

183	Interim analysis of the AVETUXIRI Trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC) A proof of concept, open-label, nonrandomized phase IIa study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 80-80	2.2	6
182	Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response <b>2020</b> , 8,		23
181	Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer. <i>JNCI Cancer Spectrum</i> , <b>2020</b> , 4, pkaa023	4.6	16
180	Immunoscore assay for the immune classification of solid tumors: Technical aspects, improvements and clinical perspectives. <i>Methods in Enzymology</i> , <b>2020</b> , 636, 109-128	1.7	7
179	Multiplexed immunohistochemistry for immune cell phenotyping, quantification and spatial distribution in situ. <i>Methods in Enzymology</i> , <b>2020</b> , 635, 51-66	1.7	8
178	Tumor Immunology and Tumor Evolution: Intertwined Histories. <i>Immunity</i> , <b>2020</b> , 52, 55-81	32.3	179
177	Genetic trajectory and immune microenvironment of lung-specific oligometastatic colorectal cancer. <i>Cell Death and Disease</i> , <b>2020</b> , 11, 275	9.8	11
176	Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer <b>2020</b> , 8,		22
175	Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with mFOLFOX6 (three versus six months) in the prospective IDEA France cohort study (PRODIGE-GERCOR).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 10-10	2.2	0
174	Immunoscore and its introduction in clinical practice. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2020</b> , 64, 152-161	1.4	22
173	The Role of the Immune Infiltrate in Distinct Cancer Types and Its Clinical Implications : Lymphocytic Infiltration in Colorectal Cancer. <i>Cancer Treatment and Research</i> , <b>2020</b> , 180, 197-211	3.5	2
172	Phenotyping of tumor infiltrating immune cells using mass-cytometry (CyTOF). <i>Methods in Enzymology</i> , <b>2020</b> , 632, 339-368	1.7	8
171	Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer. <i>Nature Medicine</i> , <b>2020</b> , 26, 919-931	50.5	55
170	The Immunoscore: Colon Cancer and Beyond. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 332-339	12.9	122
169	A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5198-5207	12.9	23
168	The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. <i>Nature Reviews Cancer</i> , <b>2020</b> , 20, 662-680	31.3	288
167	Evolution of Mutational Landscape and Tumor Immune-Microenvironment in Liver Oligo-Metastatic Colorectal Cancer. <i>Cancers</i> , <b>2020</b> , 12,	6.6	11
166	Immunity to live: an immunopathoscore using the consensus Immunoscore to best define the risk of recurrence and death in stage IV metastatic patients. <i>Onc Immunology</i> , <b>2020</b> , 9, 1826133	7.2	2

165	Usefulness and robustness of Immunoscore for personalized management of cancer patients. <i>OncImmunity</i> , <b>2020</b> , 9, 1832324	7.2	4
164	Multiverse of immune microenvironment in metastatic colorectal cancer. <i>OncImmunity</i> , <b>2020</b> , 9, 1824316	7.2	3
163	No time to die: the consensus immunescore for predicting survival and response to chemotherapy of locally advanced colon cancer patients in a multicenter international study. <i>OncImmunity</i> , <b>2020</b> , 9, 1826132	7.2	3
162	Metastasis immune-based scores predict patient survival. <i>OncImmunity</i> , <b>2020</b> , 9, 1806000	7.2	1
161	The consensus Immunoscore in phase 3 clinical trials; potential impact on patient management decisions. <i>OncImmunity</i> , <b>2020</b> , 9, 1812221	7.2	5
160	The consensus immunescore: toward a new classification of colorectal cancer. <i>OncImmunity</i> , <b>2020</b> , 9, 1789032	7.2	10
159	The Great Debate at Immunotherapy Bridge, Naples, December 5, 2019 <b>2020</b> , 8,		1
158	The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions. <i>OncImmunity</i> , <b>2020</b> , 9, 1796003	7.2	1
157	Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3638-3651	2.2	47
156	Immune evasion before tumour invasion in early lung squamous carcinogenesis. <i>Nature</i> , <b>2019</b> , 571, 570-574	5.4	123
155	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop <b>2019</b> , 7, 131		41
154	Automated exploration of gene ontology term and pathway networks with ClueGO-REST. <i>Bioinformatics</i> , <b>2019</b> , 35, 3864-3866	7.2	28
153	Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3513-3513	2.2	6
152	Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 487-487	2.2	10
151	Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. <i>Nature Reviews Drug Discovery</i> , <b>2019</b> , 18, 197-218	64.1	981
150	Comprehensive functional analysis of large lists of genes and proteins. <i>Journal of Proteomics</i> , <b>2018</b> , 171, 2-10	3.9	51
149	Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110,	9.7	155
148	Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1044	8.4	64

147	Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy) <b>2018</b> , 6, 69		10
146	International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. <i>Lancet, The</i> , <b>2018</b> , 391, 2128-2139	40	910
145	Hafnium oxide nanoparticle activated by radiotherapy to generate an anti-tumor immune response.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e15149-e15149	2.2	1
144	Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 614-614	2.2	7
143	Implications of the tumor immune microenvironment for staging and therapeutics. <i>Modern Pathology</i> , <b>2018</b> , 31, 214-234	9.8	182
142	The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients. <i>Cancer Cell</i> , <b>2018</b> , 34, 1012-1026.e3	24.3	130
141	Quantifying Immunoscore performance - AuthorsPreply. <i>Lancet, The</i> , <b>2018</b> , 392, 1624-1625	40	2
140	Evolution of Metastases in Space and Time under Immune Selection. <i>Cell</i> , <b>2018</b> , 175, 751-765.e16	56.2	207
139	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy <b>2017</b> , 5, 44		139
138	Regulation of CTL Infiltration Within the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , <b>2017</b> , 1036, 33-49	3.6	18
137	Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3025-3025	2.2	30
136	Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3579-3579	2.2	8
135	Specific adaptive immune pattern induced by NBTXR3 exposed to radiation therapy in soft tissue sarcoma (STS) patients.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e14615-e14615	2.2	2
134	Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. <i>OncolImmunology</i> , <b>2016</b> , 5, e1088631	7.2	81
133	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. <i>OncolImmunology</i> , <b>2016</b> , 5, e1214790	7.2	51
132	Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule <b>2016</b> , 4, 37		
131	31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one <b>2016</b> , 4,		8
130	Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials <b>2016</b> , 4, 15		47

129	Trial Watch-Immunostimulation with cytokines in cancer therapy. <i>OncolImmunology</i> , <b>2016</b> , 5, e1115942	7.2	35
128	Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. <i>Immunity</i> , <b>2016</b> , 44, 698-711	32.3	602
127	Frameshift mutations, neoantigens and tumor-specific CD8(+) T cells in microsatellite unstable colorectal cancers. <i>OncolImmunology</i> , <b>2016</b> , 5, e1115943	7.2	30
126	The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 327ra26	17.5	291
125	Trial Watch-Oncolytic viruses and cancer therapy. <i>OncolImmunology</i> , <b>2016</b> , 5, e1117740	7.2	76
124	Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. <i>OncolImmunology</i> , <b>2016</b> , 5, e1149674	7.2	41
123	Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. <i>OncolImmunology</i> , <b>2016</b> , 5, e1057388	7.2	176
122	Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3500-3500 <sup>2</sup>	2.2	46
121	Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. <i>International Immunology</i> , <b>2016</b> , 28, 373-82	4.9	108
120	T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells. <i>Cancer Cell</i> , <b>2016</b> , 30, 377-390	24.3	93
119	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. <i>OncolImmunology</i> , <b>2015</b> , 4, e1008814	7.2	68
118	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. <i>OncolImmunology</i> , <b>2015</b> , 4, e1008866	7.2	162
117	Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. <i>Genome Biology</i> , <b>2015</b> , 16, 64	18.3	329
116	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , <b>2015</b> , 15, 668-79	31.3	581
115	Tumor Microenvironment and Immunotherapy: The Whole Picture Is Better Than a Glimpse. <i>Immunity</i> , <b>2015</b> , 43, 631-3	32.3	43
114	Trial Watch: Adoptive cell transfer for oncological indications. <i>OncolImmunology</i> , <b>2015</b> , 4, e1046673	7.2	22
113	Trial watch: Naked and vectored DNA-based anticancer vaccines. <i>OncolImmunology</i> , <b>2015</b> , 4, e1026531	7.2	22
112	From mice to humans: developments in cancer immunoediting. <i>Journal of Clinical Investigation</i> , <b>2015</b> , 125, 3338-46	15.9	188

111	Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy. <i>Cancer Research</i> , <b>2015</b> , 75, 3446-55	10.1	148
110	Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. <i>Onc Immunology</i> , <b>2015</b> , 4, e985940	7.2	38
109	Trial Watch: Peptide-based anticancer vaccines. <i>Onc Immunology</i> , <b>2015</b> , 4, e974411	7.2	81
108	Characterization of the immune microenvironment of synchronous primary tumor and liver colorectal metastases.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3610-3610	2.2	1
107	Preoperative treatment to modify the immune microenvironment of liver colorectal metastases.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 602-602	2.2	1
106	Meta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies. <i>Oncotarget</i> , <b>2015</b> , 6, 11894-909	3.3	34
105	Prognostic association of FoxP3 regulatory T cells with tumor infiltrating CD8 cytotoxic T cells quantified on resected liver colorectal metastases (LCM).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e14643-e14643	2.2	1
104	Trial Watch: Chemotherapy with immunogenic cell death inducers. <i>Onc Immunology</i> , <b>2014</b> , 3, e27878	7.2	116
103	Prognostic and predictive values of the immunoscore in patients with rectal cancer. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 1891-9	12.9	230
102	30: From the immune contexture to the Immunoscore in cancer. <i>European Journal of Cancer</i> , <b>2014</b> , 50, S8	7.5	1
101	Trial Watch: Adoptive cell transfer for anticancer immunotherapy. <i>Onc Immunology</i> , <b>2014</b> , 3, e28344	7.2	30
100	Towards the introduction of the Immunoscore in the classification of malignant tumours. <i>Journal of Pathology</i> , <b>2014</b> , 232, 199-209	9.4	882
99	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , <b>2014</b> , 5, 12472-508	3.3	301
98	Trial watch: Immunostimulatory cytokines in cancer therapy. <i>Onc Immunology</i> , <b>2014</b> , 3, e29030	7.2	47
97	Consensus guidelines for the detection of immunogenic cell death. <i>Onc Immunology</i> , <b>2014</b> , 3, e955691	7.2	524
96	Trial Watch: Toll-like receptor agonists in oncological indications. <i>Onc Immunology</i> , <b>2014</b> , 3, e29179	7.2	61
95	Trial Watch: Radioimmunotherapy for oncological indications. <i>Onc Immunology</i> , <b>2014</b> , 3, e954929	7.2	36
94	Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. <i>Onc Immunology</i> , <b>2014</b> , 3, e27048.2	7.2	64

93	Trial Watch: DNA vaccines for cancer therapy. <i>Onc Immunology</i> , <b>2014</b> , 3, e28185	7.2	33
92	Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. <i>Onc Immunology</i> , <b>2014</b> , 3, e27297	7.2	86
91	The immune landscape of human tumors: Implications for cancer immunotherapy. <i>Onc Immunology</i> , <b>2014</b> , 3, e27456	7.2	75
90	Trial Watch:: Oncolytic viruses for cancer therapy. <i>Onc Immunology</i> , <b>2014</b> , 3, e28694	7.2	88
89	Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy. <i>Onc Immunology</i> , <b>2014</b> , 3, e27884	7.2	61
88	Trial watch: Dendritic cell-based anticancer therapy. <i>Onc Immunology</i> , <b>2014</b> , 3, e963424	7.2	54
87	Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. <i>Science Translational Medicine</i> , <b>2014</b> , 6, 228ra37	17.5	141
86	Immunoguiding, the Final Frontier in the Immunotherapy of Cancer <b>2014</b> , 37-51		
85	The immune microenvironment of human tumors: general significance and clinical impact. <i>Cancer Microenvironment</i> , <b>2013</b> , 6, 117-22	6.1	93
84	Focus on the target: the tumor microenvironment, Society for Immunotherapy of Cancer Annual Meeting Workshop, October 24th-25th 2012 <b>2013</b> , 1, 9		2
83	Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. <i>Immunity</i> , <b>2013</b> , 39, 782-95	32.3	1595
82	From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. <i>Current Opinion in Immunology</i> , <b>2013</b> , 25, 261-7	7.8	325
81	The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. <i>Immunity</i> , <b>2013</b> , 39, 11-26	32.3	554
80	Trial watch: DNA vaccines for cancer therapy. <i>Onc Immunology</i> , <b>2013</b> , 2, e23803	7.2	70
79	Trial watch: Dendritic cell-based interventions for cancer therapy. <i>Onc Immunology</i> , <b>2013</b> , 2, e25771	7.2	87
78	Trial Watch: Lenalidomide-based immunochemotherapy. <i>Onc Immunology</i> , <b>2013</b> , 2, e26494	7.2	39
77	Trial watch: Monoclonal antibodies in cancer therapy. <i>Onc Immunology</i> , <b>2013</b> , 2, e22789	7.2	76
76	Trial watch: Chemotherapy with immunogenic cell death inducers. <i>Onc Immunology</i> , <b>2013</b> , 2, e23510	7.2	72



75	Trial Watch: Peptide vaccines in cancer therapy. <i>Oncolmunology</i> , <b>2013</b> , 2, e26621	7.2	84
74	Trial Watch: Adoptive cell transfer for anticancer immunotherapy. <i>Oncolmunology</i> , <b>2013</b> , 2, e24238	7.2	43
73	Trial Watch: Immunostimulatory cytokines. <i>Oncolmunology</i> , <b>2013</b> , 2, e24850	7.2	44
72	Trial Watch: Anticancer radioimmunotherapy. <i>Oncolmunology</i> , <b>2013</b> , 2, e25595	7.2	75
71	Trial Watch: Toll-like receptor agonists for cancer therapy. <i>Oncolmunology</i> , <b>2013</b> , 2, e25238	7.2	120
70	CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data. <i>Bioinformatics</i> , <b>2013</b> , 29, 661-3	7.2	650
69	Trial watch: Oncolytic viruses for cancer therapy. <i>Oncolmunology</i> , <b>2013</b> , 2, e24612	7.2	94
68	Integrating Biomolecular and Clinical Data for Cancer Research: Concepts and Challenges <b>2012</b> , 159-172		
67	Bioinformatics for cancer immunology and immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , <b>2012</b> , 61, 1885-903	7.4	32
66	Cancer classification using the Immunoscore: a worldwide task force. <i>Journal of Translational Medicine</i> , <b>2012</b> , 10, 205	8.5	538
65	Trial watch: Dendritic cell-based interventions for cancer therapy. <i>Oncolmunology</i> , <b>2012</b> , 1, 1111-1134	7.2	134
64	Trial Watch: Monoclonal antibodies in cancer therapy. <i>Oncolmunology</i> , <b>2012</b> , 1, 28-37	7.2	80
63	Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. <i>Oncolmunology</i> , <b>2012</b> , 1, 1323-1343	7.2	173
62	The immune contexture in human tumours: impact on clinical outcome. <i>Nature Reviews Cancer</i> , <b>2012</b> , 12, 298-306	31.3	2819
61	Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. <i>Oncolmunology</i> , <b>2012</b> , 1, 894-907	7.2	163
60	Trial watch: Chemotherapy with immunogenic cell death inducers. <i>Oncolmunology</i> , <b>2012</b> , 1, 179-188	7.2	86
59	Trial watch: Peptide vaccines in cancer therapy. <i>Oncolmunology</i> , <b>2012</b> , 1, 1557-1576	7.2	73
58	Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. <i>Oncolmunology</i> , <b>2012</b> , 1, 699-716	7.2	164

57	Trial Watch: Adoptive cell transfer immunotherapy. <i>Onc Immunology</i> , <b>2012</b> , 1, 306-315	7.2	58
56	Trial Watch: Immunostimulatory cytokines. <i>Onc Immunology</i> , <b>2012</b> , 1, 493-506	7.2	66
55	Prognostic and predictive impact of intra- and peritumoral immune infiltrates. <i>Cancer Research</i> , <b>2011</b> , 71, 5601-5	10.1	297
54	The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. <i>Frontiers in Immunology</i> , <b>2011</b> , 2, 66	8.4	7
53	Cancer immunology--analysis of host and tumor factors for personalized medicine. <i>Nature Reviews Clinical Oncology</i> , <b>2011</b> , 8, 711-9	19.4	209
52	Tumor immunosurveillance in human cancers. <i>Cancer and Metastasis Reviews</i> , <b>2011</b> , 30, 5-12	9.6	123
51	hSMG-1 is a granzyme B-associated stress-responsive protein kinase. <i>Journal of Molecular Medicine</i> , <b>2011</b> , 89, 411-21	5.5	6
50	The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. <i>Seminars in Immunopathology</i> , <b>2011</b> , 33, 335-40	12	82
49	Immune infiltration in human cancer: prognostic significance and disease control. <i>Current Topics in Microbiology and Immunology</i> , <b>2011</b> , 344, 1-24	3.3	126
48	Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 610-8	2.2	692
47	Immunosurveillance in human non-viral cancers. <i>Current Opinion in Immunology</i> , <b>2011</b> , 23, 272-8	7.8	37
46	Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. <i>Cancer Research</i> , <b>2011</b> , 71, 1263-71	10.1	773
45	D/2 Predictors of Favorable Outcome in Cancer <b>2011</b> , 199-210		
44	Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. <i>Gastroenterology</i> , <b>2010</b> , 138, 1429-40	13.3	228
43	Information technology solutions for integration of biomolecular and clinical data in the identification of new cancer biomarkers and targets for therapy. <i>Pharmacology &amp; Therapeutics</i> , <b>2010</b> , 128, 488-98	13.9	10
42	Data integration and exploration for the identification of molecular mechanisms in tumor-immune cells interaction. <i>BMC Genomics</i> , <b>2010</b> , 11 Suppl 1, S7	4.5	15
41	Natural immunity to cancer in humans. <i>Current Opinion in Immunology</i> , <b>2010</b> , 22, 215-22	7.8	129
40	Memory T-cell responses and survival in human cancer: remember to stay alive. <i>Advances in Experimental Medicine and Biology</i> , <b>2010</b> , 684, 166-77	3.6	8

39	ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. <i>Bioinformatics</i> , <b>2009</b> , 25, 1091-3	7.2	3395
38	In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5944-51	2.2	666
37	Coordination of intratumoral immune reaction and human colorectal cancer recurrence. <i>Cancer Research</i> , <b>2009</b> , 69, 2685-93	10.1	200
36	The essential role of the in situ immune reaction in human colorectal cancer. <i>Journal of Leukocyte Biology</i> , <b>2008</b> , 84, 981-7	6.5	84
35	The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. <i>Cancer Research</i> , <b>2007</b> , 67, 1883-6	10.1	298
34	Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 1428-33	11.5	43
33	Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. <i>Science</i> , <b>2006</b> , 313, 1960-4	33.3	4329
32	Effector memory T cells, early metastasis, and survival in colorectal cancer. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 2654-66	59.2	1560
31	Epstein-Barr virus nuclear antigen 2 induces interleukin-18 receptor expression in B cells. <i>Blood</i> , <b>2005</b> , 105, 1632-9	2.2	20
30	Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. <i>FASEB Journal</i> , <b>2002</b> , 16, 61-71	0.9	447
29	Cybr, a cytokine-inducible protein that binds cytohesin-1 and regulates its activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2002</b> , 99, 2625-9	11.5	36
28	Positive effects of glucocorticoids on T cell function by up-regulation of IL-7 receptor alpha. <i>Journal of Immunology</i> , <b>2002</b> , 168, 2212-8	5.3	128
27	Glucocorticoids and inflammation revisited: the state of the art. NIH clinical staff conference. <i>NeuroImmunoModulation</i> , <b>2002</b> , 10, 247-60	2.5	91
26	Modulation of tumor growth by inhibitory Fcγ receptor expressed by human melanoma cells. <i>Journal of Clinical Investigation</i> , <b>2002</b> , 110, 1549-1557	15.9	26
25	Modulation of tumor growth by inhibitory Fc(γ) receptor expressed by human melanoma cells. <i>Journal of Clinical Investigation</i> , <b>2002</b> , 110, 1549-57	15.9	10
24	Soluble CD16 inhibits CR3 (CD11b/CD18)-mediated infection of monocytes/macrophages by opsonized primary R5 HIV-1. <i>Journal of Immunology</i> , <b>2001</b> , 166, 3377-83	5.3	30
23	The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. <i>American Journal of Human Genetics</i> , <b>2001</b> , 69, 301-14	11	277
22	TNFRSF1A mutations and autoinflammatory syndromes. <i>Current Opinion in Immunology</i> , <b>2000</b> , 12, 479-86.8	19.3	193

21	Do glucocorticoids participate in thymocyte development?. <i>Trends in Immunology</i> , <b>2000</b> , 21, 644-6		34
20	The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. <i>Blood</i> , <b>2000</b> , 95, 3223-3231	2.2	306
19	Stat4 is expressed in activated peripheral blood monocytes, dendritic cells, and macrophages at sites of Th1-mediated inflammation. <i>Journal of Immunology</i> , <b>2000</b> , 164, 4659-64	5.3	144
18	Inhibition of Th1 immune response by glucocorticoids: dexamethasone selectively inhibits IL-12-induced Stat4 phosphorylation in T lymphocytes. <i>Journal of Immunology</i> , <b>2000</b> , 164, 1768-74	5.3	196
17	Hierarchy of protein tyrosine kinases in interleukin-2 (IL-2) signaling: activation of syk depends on Jak3; however, neither Syk nor Lck is required for IL-2-mediated STAT activation. <i>Molecular and Cellular Biology</i> , <b>2000</b> , 20, 4371-80	4.8	35
16	Adrenal cortical activation in murine colitis. <i>Gastroenterology</i> , <b>2000</b> , 119, 1560-8	13.3	41
15	The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. <i>Blood</i> , <b>2000</b> , 95, 3223-3231	2.2	10
14	Presentation of antigen in immune complexes is boosted by soluble bacterial immunoglobulin binding proteins. <i>Journal of Experimental Medicine</i> , <b>1999</b> , 189, 1217-28	16.6	10
13	Regulation of production of soluble Fc gamma receptors type III in normal and pathological conditions. <i>Immunology Letters</i> , <b>1999</b> , 68, 125-34	4.1	34
12	Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. <i>Cell</i> , <b>1999</b> , 97, 133-44	56.2	1008
11	Identification of the cleavage site involved in production of plasma soluble Fc gamma receptor type III (CD16). <i>European Journal of Immunology</i> , <b>1998</b> , 28, 2101-7	6.1	35
10	Soluble Fc gamma receptors: interaction with ligands and biological consequences. <i>International Reviews of Immunology</i> , <b>1997</b> , 16, 87-111	4.6	18
9	A new set of monoclonal antibodies against human Fc gamma RII (CD32) and Fc gamma RIII (CD16): characterization and use in various assays. <i>Hybridoma</i> , <b>1997</b> , 16, 519-28		31
8	Affinity of the interaction between Fc gamma receptor type III (Fc gammaRIII) and monomeric human IgG subclasses. Role of Fc gammaRIII glycosylation. <i>European Journal of Immunology</i> , <b>1997</b> , 27, 1928-32	6.1	45
7	Regulation of CD44 isoform expression and CD44-mediated signaling in human dendritic cells. <i>Advances in Experimental Medicine and Biology</i> , <b>1997</b> , 417, 83-90	3.6	6
6	Ligands and biological activities of soluble Fc gamma receptors. <i>Immunology Letters</i> , <b>1995</b> , 44, 175-81	4.1	22
5	Soluble Fc gamma receptors. <i>Journal of Leukocyte Biology</i> , <b>1993</b> , 54, 504-512	6.5	47
4	Janus Kinases and STAT Family Transcription Factors: Their Role in the Function and Development of Lymphoid Cells 229-254		

- 3 Germline genetic contribution to the immune landscape of cancer 2
- 2 Conditional activation of immune-related signatures and prognostic significance: a pan-cancer analysis 2
- 1 Tissue-resident FOLR2+ macrophages associate with tumor-infiltrating CD8+ T cells and with increased survival of breast cancer patients 2